biotech

biotech Articles

Biogen released its third-quarter financial results and Alzheimer’s trial news before the markets opened on Tuesday.
Seattle Genetics shares jumped on Monday after the firm announced positive results from its midstage breast cancer trial.
Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.
Axsome Therapeutics shares made a handy gain on Wednesday after the firm announced that it has completed patient enrollment in its Gemini study, a Phase 3 trial of AXS-05 in patients with major...
Achillion Pharmaceuticals shares skyrocketed on Wednesday morning on news that the firm would be acquired by Alexion Pharmaceuticals.
Reata Pharma shares jumped on Tuesday after the firm announced positive results from its midstage neuromuscular disorder drug trial.
Flexion Therapeutics has announced that the FDA needs additional time to complete the review of its osteoarthritis knee pain treatment.
Ra Pharmaceuticals shares more than doubled on Thursday after the announcement that UCB would acquire the firm.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The September 30 short interest data has been compared with the previous report, and short interest in...
Now, Mereo BioPharma is taking steps towards a solution to ovarian cancer with its most recent update from the FDA.
DBV Technologies shares dipped on Monday after the firm announced an update from the FDA. Although it was a positive update for the company, this appears to be a case of “sell the news.”
Sarepta shares jumped on Friday after the firm announced an update from its Duchenne muscular dystrophy trial.
These three biotech stocks have upcoming clinical data and presentations that could be huge, and they could blast the stocks higher.
Minerva Neurosciences shares dropped sharply on Tuesday after the firm announced that it was the victim of a cyberattack. Minerva also provided an update on its clinical trials.
Catabasis Pharma shares jumped early on Tuesday after the firm announced that it had completed the enrollment for its late-stage Duchenne muscular dystrophy (DMD) study. Specifically, the enrollment...